Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Harvard Business School
Merck
Express Scripts
Colorcon

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

LUSEDRA Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Lusedra, and when can generic versions of Lusedra launch?

Lusedra is a drug marketed by Eisai Inc and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-four patent family members in twenty-five countries.

The generic ingredient in LUSEDRA is fospropofol disodium. Additional details are available on the fospropofol disodium profile page.

Summary for LUSEDRA
Drug patent expirations by year for LUSEDRA
Generic Entry Opportunity Date for LUSEDRA
Generic Entry Date for LUSEDRA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LUSEDRA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Grace Shih, MDN/A
Mayo ClinicPhase 4
Eisai Inc.Phase 1

See all LUSEDRA clinical trials

Recent Litigation for LUSEDRA

Identify potential future generic entrants

District Court Litigation
Case NameDate
Allergan Inc. v. Alcon Inc.2004-08-24

See all LUSEDRA litigation

Synonyms for LUSEDRA
258516-87-9
30868AY0IF
AC-25763
AC1MI4YF
ACN-049983
AKOS024406472
AN-3709
Aquavan
Aquavan (TN)
Aquavan injection
CHEMBL2021422
D04257
DEA No. 2138
dipotassium 2,6-diisopropylphenoxymethyl phosphate
disodium (2,6-diisopropylphenoxy)methyl phosphate
disodium [2,6-di(propan-2-yl)phenoxy]methyl phosphate
DTXSID10180504
Fospropofol disodium
Fospropofol disodium (USAN)
Fospropofol disodium [USAN]
Fospropofol disodium salt
GPI 15715
GPI-15715
KB-52180
LS-192060
Lusedra (TN)
Methanol, (2,6-bis(1-methylethyl)phenoxy)-, dihydrogen phosphate, disodium salt
phosphoric acid 2,6-diisopropylphenoxymethyl monoester disodium salt
PQ-1002
UNII-30868AY0IF

US Patents and Regulatory Information for LUSEDRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc LUSEDRA fospropofol disodium SOLUTION;INTRAVENOUS 022244-001 Dec 12, 2008 DISCN No No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Mallinckrodt
Johnson and Johnson
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.